医护人员接种BNT162b2新冠mRNA疫苗后的抗刺突S1 IgA、抗刺突三聚体IgG和抗刺突RBD IgG反应。
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers.
作者信息
Salvagno Gian Luca, Henry Brandon M, di Piazza Giovanni, Pighi Laura, de Nitto Simone, Bragantini Damiano, Gianfilippi Gian Luca, Lippi Giuseppe
机构信息
University of Verona, Section of Clinical Biochemistry, Verona, Italy.
Pederzoli Hospital, Service of Laboratory Medicine, Peschiera del Garda, Italy.
出版信息
J Med Biochem. 2021 Sep 3;40(4):327-334. doi: 10.5937/jomb0-32373.
BACKGROUND
Most studies on immune response after coronavirus disease 2019 (COVID-19) vaccination focused on serum IgG antibodies and cell-mediated immunity, discounting the role of anti-SARS-CoV-2 neutralizing IgA antibodies in preventing viral infection. This study was aimed to quantify serum IgG and IgA neutralizing antibodies after mRNA COVID-19 vaccination in baseline SARS-CoV-2 seronegative healthcare workers.
METHODS
The study population consisted of 181 SARSCoV-2 seronegative healthcare workers (median age 42 years, 59.7% women), receiving two doses of Pfizer COVID-19 vaccine BNT162b2 (Comirnaty). Serum samples were collected before receiving the first vaccine dose, 21 days (before the second vaccine dose) and 50 days afterwards. We then measured anti-spike trimeric IgG (Liaison XL, DiaSorin), anti-spike receptor binding domain (RBD) IgG (Access 2, Beckman Coulter) and anti-spike S1 subunit IgA (ELISA, Euroimmun). Results were presented as median and interquartile range (IQR).
RESULTS
Vaccine administration elicited all anti-SARS-CoV2 antibodies measured. Thirty days after the second vaccine dose, 100% positivization occurred for anti-spike trimeric IgG and anti-spike RBD IgG, whilst 1.7% subjects remained anti-spike S1 IgA negative. The overall increase of antibodies level ratio over baseline after the second vaccine dose was 576.1 (IQR, 360.7-867.8) for anti-spike trimeric IgG, 1426.0 (IQR, 742.0-2698.6) for anti-spike RBD IgG, and 20.2 (IQR, 12.5-32.1) for anti-spike S1 IgA. Significant inverse association was found between age and overall increase of anti-spike trimeric IgG (r=-0.24; p=0.001) and anti-spike S1 IgA (r=-0.16; p=0.028), but not with anti-spike RBD IgG (r=-0.05; p=0.497).
CONCLUSIONS
mRNA COVID-19 vaccination elicits sustained serum levels of anti-spike trimeric IgG and anti-spike RBD IgG, while also modestly but significantly increasing those of anti-spike S1 IgA.
背景
大多数关于2019冠状病毒病（COVID-19）疫苗接种后免疫反应的研究都集中在血清IgG抗体和细胞介导的免疫上，而忽视了抗SARS-CoV-2中和IgA抗体在预防病毒感染中的作用。本研究旨在量化基线SARS-CoV-2血清阴性医护人员接种mRNA COVID-19疫苗后血清中的IgG和IgA中和抗体。
方法
研究对象为181名SARS-CoV-2血清阴性医护人员（中位年龄42岁，女性占59.7%），他们接种了两剂辉瑞COVID-19疫苗BNT162b2（Comirnaty）。在接种第一剂疫苗前、21天（接种第二剂疫苗前）和之后50天采集血清样本。然后我们检测了抗刺突三聚体IgG（Liaison XL，DiaSorin）、抗刺突受体结合域（RBD）IgG（Access 2，Beckman Coulter）和抗刺突S1亚基IgA（ELISA，Euroimmun）。结果以中位数和四分位数间距（IQR）表示。
结果
疫苗接种引发了所有检测的抗SARS-CoV-2抗体。在接种第二剂疫苗30天后，抗刺突三聚体IgG和抗刺突RBD IgG的阳性率均达到100%，而1.7%的受试者抗刺突S1 IgA仍为阴性。接种第二剂疫苗后，抗刺突三聚体IgG的抗体水平比基线总体升高576.1（IQR，360.7 - 867.8），抗刺突RBD IgG为1426.0（IQR，742.0 - 2698.6），抗刺突S1 IgA为20.2（IQR，12.5 - 32.1）。年龄与抗刺突三聚体IgG（r = -0.24；p = 0.001）和抗刺突S1 IgA（r = -0.16；p = 0.028）的总体升高之间存在显著负相关，但与抗刺突RBD IgG（r = -0.05；p = 0.497）无关。
结论
mRNA COVID-19疫苗接种可使抗刺突三聚体IgG和抗刺突RBD IgG的血清水平持续升高，同时也适度但显著地提高了抗刺突S1 IgA的血清水平。
Zotero 插件